🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07020169
Recruiting Not applicable

Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study

NCT07020169 · tracked via the Priya Life Science China tracker
Sponsor
Shao Pengfei
Phase
Not applicable
Started
2025-05-01
Last updated
2025-06-13

Condition(s) studied

Renal Cell Cancer

Investigational drug(s) / intervention(s)

an AI-based real-time image-guided kidney model system

an AI-based real-time image-guided kidney model system: Use the AI-model to locate kidney and tumour, assisting surgeon with the operation

Study summary

The goal of this study is to develop a real-time artificial intelligence-driven 3D kidney model to assist robotic or laparoscopic partial nephrectomy:

• Can this AI-powered model optimize the workflow of partial nephrectomy and enhance surgical benefits?

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Ages 18-80 years, regardless of gender * Written informed consent obtained from the patient or legally authorized representative after full protocol disclosure * Preoperative imaging (CT/MRI) confirming clinical stage T1a or select T1b renal tumors suitable for partial nephrectomy (R.E.N.A.L. nephrometry score ≤10) * Localized renal tumors without lymph node/distant metastasis per NCCN Guidelines® (v2023) * Elective minimally invasive partial nephrectomy (laparoscopic/robotic) after comprehensive surgical counseling Exclusion Criteria: * Multifocal renal tumors (bilateral or unilateral) * Prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy) within 6 months * Absolute surgical contraindications (e.g., ASA class ≥IV, uncontrolled coagulopathy) * Intraoperative conversion to radical nephrectomy or open approach * Postoperative adjuvant therapy during protocol-defined follow-up (12 months) * Major comorbidities (e.g., NYHA class III/IV heart failure, eGFR \<30 mL/min/1.73m²) affecting outcome assessment * Concurrent enrollment in interventional clinical trials * Investigator-determined ineligibility based on risk-benefit analysis

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) Nanjing Jiangsu Not Yet Recruiting
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital) Nanjing Jiangsu Recruiting

More Shao Pengfei trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07020169 on ClinicalTrials.gov ↗ ← All trials in China